Companion Animal Drugs Industry to Reach US$59.2 Billion by 2033, Driven by Rising Pet Ownership and Increasing Demand for Premium Pet Products

The global Companion Animal Drugs Industry is predicted to increase at a 4.4% CAGR to US$ 59.2 billion by the end of 2033, up from US$ 36.7 billion in 2022.

Pets are given companion animal medications to keep them healthy and protected from infections and other health problems. When an animal undergoes surgery, a companion animal veterinarian administers medications to cure wounds, diagnose various ailments, and so on.

Companion animal medications are essential for keeping pets healthy while also protecting the entire family who cares for them from any health risks that the pets may pose. Companion animal drugs are regularly used by dogs, cats, horses, and other companion animals.

Action Required: Download Now to Unleash the Power of Companion Animal Drugs Industry! @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1077

Increasing Urbanization and Growing Affluence in Developing Countries to Benefit the Market
Increasing urbanization level and growing affluence, especially in developing countries, have been driving the adoption of pets, thus leading to increased demand for healthcare products for pets such as companion animal drugs. Continued urbanization has also resulted in increasing prevalence of various diseases such as allergies, lower appetite, reduced energy and behavioral anxieties among small companion animals. This has been driving the demand for innovative classes of medicines such as companion animal drugs.

Upcoming Therapeutic Innovations in Pet Care to Aid Market Growth
Besides traditional drugs, animal health companies have also been investing in smart diagnostic care to help prevent diseases before the actual onset. Companies are also trying to develop generic capabilities to demonstrate bioequivalence to reference prescription drugs in the companion animal drugs market, as many key drugs no longer benefit from intellectual property protection. The development of new vaccines and medications for animals are expected to support the growth of the Companion Animal Drugs Industry over the forecast period.

Increasing R&D activities and shorter drug-lifecycle are playing an important role in the growth of the companion animal drugs market. Innovations in companion animal drugs are easier and sustainable for a longer period of time, while R&D cycle time are shorter (~ three years) in the Companion Animal Healthcare (CAH) industry as compared to human health, ranging between seven and 15 years for other drugs. This increases return on investment in companion animal drugs and leads to faster profits for the market players.

Enjoy Up to 30% Discount on Customizing this Report. @ https://www.futuremarketinsights.com/request-discount/rep-gb-1077

Collaborative Ventures to Promote the Companion Animal Drugs Industry Growth
Collaborative ventures such as One Health promotes unification of veterinary and medical sciences, leading to better disease surveillance, control and education, especially for companion animals such as dogs and cats. One Health venture enables identification of alteration in infection travelling patterns. The patterns are changing mostly in case of parasites due to change in climate and increasing host-vector interactions. Some organizations helping in monitoring of One Health in companion animals are Companion Animal Parasite Council and European Scientific Counsel Companion Animal Parasites.

Such ventures are expected to complement the growth of the Companion Animal Drugs Industry

Low Awareness of Animal Diseases to Hamper the Companion Animal Drugs Industry Growth
In many developing countries, people lack awareness regarding certain serious companion animal diseases as opposed to livestock diseases, which are more regularly monitored. This is primarily true with regards to pet vaccinations, which is a mandatory requirement for up to three years. Additionally, parasitic medications for companion animals and livestock are different. Lack of awareness with regards to differentiation of these medication varieties leads to adverse drug side effects and thus low administration of companion animal medications. Such factors are likely to create a hindrance in the growth of the Companion Animal Drugs Industry.

Also, majority of animal healthcare drugs have limited scope for patent extension, primarily due to drug portfolios dominated by drugs that have crossed maturity, which in turn is expected to deter the growth of the Companion Animal Drugs Industry over the forecast period.

Key Players in the Companion Animal Drugs Industry:

• Zoetis Inc.
• Merck & Co, Ltd.
• Bayer AG
• Elanco
• Boehringer Ingelheim GmbH (Merial)
• Virbac Animal Health
• Ceva Santè Animale

Exclusive Customizations Available: Request Tailored Insights to Outperform in the Companion Animal Drugs Industry! @ https://www.futuremarketinsights.com/customization-available/rep-gb-1077

Key Segments Covered in Companion Animal Drugs Industry Research

Product:

• Antibiotics
• Anti-inflammatory
• Parasiticides
• Heartworm
• Behavioral Products
• Nutritional Products
• Skin Care Products
• Vaccines

Distributional Channel:

• Veterinary Hospitals
• Veterinary Clinics
• Pharmacies and Drug Stores

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:          

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube